Skip to content

Fluoxetine

SSRI Antidepressant — CNS & Neurological

Data last refreshed: (DrugCentral release 2024-11-01) · Article last edited:

Key facts

Fluoxetine is an ofp drug in the Serotonin Reuptake Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1987. Its mechanism of action is classified as Serotonin Uptake Inhibitors. DrugCentral lists 41 molecular targets, including SLC6A4, Slc6a4 and ADRA2A. Recorded indications include Bipolar affective disorder, current episode depression, Bulimia nervosa, Depressive disorder and Major depressive disorder.

  • Approval status: ofp (first approved 1987 by the FDA).
  • Drug class: Serotonin Reuptake Inhibitor.
  • Mechanism of action: Serotonin Uptake Inhibitors.
  • Molecular targets: SLC6A4, Slc6a4, ADRA2A and Slc6a3 (41 listed in DrugCentral).
  • Indications: Bipolar affective disorder, current episode depression, Bulimia nervosa, Depressive disorder, Major depressive disorder and Obsessive-compulsive disorder and others.
  • ATC code: N06AB03 (Selective serotonin reuptake inhibitors).
  • Molecular formula: C17H18F3NO; molecular weight 309.33 g/mol.

The guide below was drafted with an AI model (Google Gemini) and edited automatically; it is not clinically reviewed. The data sections after it come directly from DrugCentral. How we generate and check text.

What is Fluoxetine?

Fluoxetine, widely recognized by its original brand name Prozac, is a cornerstone medication in the treatment of various mental health conditions. As a member of the selective serotonin reuptake inhibitor (SSRI) class of antidepressants, it has profoundly impacted the management of depression, obsessive-compulsive disorder (OCD), panic disorder, and other mood and anxiety disorders since its introduction. Fluoxetine works by modulating the levels of serotonin, a key neurotransmitter in the brain, thereby helping to alleviate symptoms associated with these conditions. Available in various generic forms and under different brand names globally, fluoxetine remains a vital therapeutic option for millions of individuals seeking relief from debilitating psychological distress. This page covers its mechanism of action, clinical applications, safety profile, and molecular characteristics.

Mechanism of Action

Fluoxetine exerts its therapeutic effects primarily by targeting the serotonergic system in the central nervous system (CNS). Its classification as a selective serotonin reuptake inhibitor (SSRI) is central to understanding its pharmacological action. In a healthy brain, neurons communicate through chemical messengers called neurotransmitters. Serotonin (5-hydroxytryptamine, or 5-HT) is a critical neurotransmitter involved in regulating mood, emotion, sleep, appetite, and other cognitive functions. After serotonin is released into the synaptic cleft (the space between two neurons) to transmit a signal, it is typically reabsorbed back into the presynaptic neuron through a process called reuptake. This reuptake is mediated by a specific protein transporter, the serotonin transporter (SERT).

Fluoxetine functions by selectively blocking the SERT. By inhibiting the reuptake of serotonin, fluoxetine effectively increases the concentration of serotonin available in the synaptic cleft. This enhanced availability allows serotonin to bind more readily and for longer durations to postsynaptic receptors, thereby amplifying serotonergic neurotransmission. This increased signaling is believed to be responsible for the gradual improvement in mood and reduction in anxiety and other symptoms experienced by patients taking fluoxetine.

Receptor Interactions

While the primary mechanism of fluoxetine involves SERT inhibition, it's important to note that SSRIs can have complex interactions with various serotonin receptor subtypes. Fluoxetine exhibits relatively low affinity for other neurotransmitter receptors, such as adrenergic, histaminergic, muscarinic, and dopaminergic receptors. This selectivity contributes to its favorable side effect profile compared to older classes of antidepressants like tricyclic antidepressants (TCAs) or monoamine oxidase inhibitors (MAOIs), which often have broader receptor binding and consequently more side effects.

Over time, chronic administration of fluoxetine leads to adaptive changes in the brain, including potential alterations in the sensitivity and density of serotonin receptors, as well as downstream effects on other neurotransmitter systems. These neuroadaptive changes are thought to underlie the therapeutic benefits that typically take several weeks to become fully apparent.

Clinical Uses & Indications

Fluoxetine is FDA-approved for a range of psychiatric conditions, offering relief to individuals suffering from significant mood and anxiety disturbances. Its efficacy and relatively good tolerability have made it a first-line treatment option for many of these disorders.

Major Depressive Disorder (MDD)

The most common indication for fluoxetine is the treatment of major depressive disorder. It is effective in alleviating the core symptoms of depression, including persistent sadness, loss of interest or pleasure (anhedonia), changes in appetite and sleep, fatigue, feelings of worthlessness or guilt, difficulty concentrating, and recurrent thoughts of death or suicide. Fluoxetine can be used for acute treatment of depressive episodes and for long-term maintenance therapy to prevent relapse.

Obsessive-Compulsive Disorder (OCD)

Fluoxetine is also indicated for the treatment of OCD in both adults and children. OCD is characterized by recurrent, intrusive thoughts (obsessions) and repetitive behaviors or mental acts (compulsions) that individuals feel driven to perform. By increasing serotonin levels, fluoxetine helps to reduce the severity and frequency of obsessions and compulsions.

Panic Disorder

This condition involves recurrent, unexpected panic attacks and persistent worry about having more attacks. Fluoxetine has demonstrated efficacy in reducing the frequency and intensity of panic attacks and alleviating the anticipatory anxiety associated with the disorder.

Bulimia Nervosa

Fluoxetine is approved for the treatment of bulimia nervosa, an eating disorder characterized by recurrent episodes of binge eating followed by compensatory behaviors such as self-induced vomiting, misuse of laxatives, or excessive exercise. It is particularly effective in reducing binge eating and purging behaviors.

Premenstrual Dysphoric Disorder (PMDD)

PMDD is a severe form of premenstrual syndrome (PMS) characterized by significant mood swings, irritability, depression, and anxiety in the week or two before menstruation. Fluoxetine can help manage these debilitating mood symptoms.

Other Off-Label Uses

While not FDA-approved for these conditions, fluoxetine is sometimes prescribed off-label by healthcare providers for other conditions, including generalized anxiety disorder (GAD), social anxiety disorder (SAD), post-traumatic stress disorder (PTSD), attention-deficit/hyperactivity disorder (ADHD), and binge eating disorder, often as an adjunct to other therapies.

Dosage & Administration

The dosage of fluoxetine must be individualized based on the patient's condition, response, and tolerability. It is crucial to follow the prescribing physician's instructions carefully and not to alter the dosage or discontinue the medication without medical consultation.

Dosage Forms

Fluoxetine is available in several dosage forms to accommodate different patient needs and preferences:

  • Capsules: Typically available in strengths of 10 mg, 20 mg, 30 mg, 40 mg, and 60 mg.
  • Tablets: Similar strengths to capsules, sometimes with extended-release formulations.
  • Oral Solution: A liquid form, often available in strengths like 20 mg/5 mL, which can be useful for children or individuals who have difficulty swallowing pills.
  • Delayed-Release Capsules: Formulations designed for once-weekly dosing (e.g., 90 mg).

Administration

Fluoxetine can be taken with or without food. For standard formulations (capsules and oral solution), it is typically administered once daily. Due to its long half-life, the timing of administration is less critical than with some other antidepressants, but taking it around the same time each day can help maintain consistent drug levels.

For patients experiencing insomnia, taking the daily dose in the morning is often recommended. For those with significant daytime sedation or if a particular dose causes agitation, adjusting the timing might be considered under medical supervision.

Starting and Titrating Dose

The starting dose for fluoxetine often varies depending on the indication:

  • Major Depressive Disorder: Typically starts at 20 mg once daily. The dose may be increased to 40 mg or 60 mg per day, and sometimes up to 80 mg per day, depending on the patient's response. Doses above 60 mg daily are usually divided into two doses.
  • OCD: Often requires higher doses, starting at 20 mg and potentially increasing to 60 mg or 80 mg per day.
  • Bulimia Nervosa: The recommended dose is 60 mg per day.
  • PMDD: Can be taken daily (e.g., 20 mg per day) or intermittently during the luteal phase of the menstrual cycle (e.g., 20 mg per day from two weeks before expected menses through the first day of the period).

It is essential to allow adequate time for the medication to take effect, as therapeutic benefits may not be noticeable for several weeks. Dose adjustments should be made gradually under the guidance of a healthcare professional.

Side Effects & Safety

Like all medications, fluoxetine can cause side effects, ranging from mild to severe. Understanding these potential effects is crucial for patients and their healthcare providers.

Common Side Effects

The most frequently reported side effects of fluoxetine include:

  • Nausea
  • Headache
  • Insomnia or somnolence (drowsiness)
  • Anxiety or nervousness
  • Diarrhea
  • Dry mouth
  • Decreased appetite and weight loss
  • Sexual dysfunction (e.g., decreased libido, difficulty achieving orgasm, erectile dysfunction)
  • Sweating
  • Tremor

Many of these side effects are dose-dependent and may lessen or resolve over time as the body adjusts to the medication.

Serious Side Effects

While less common, some side effects require immediate medical attention:

  • Serotonin Syndrome: A potentially life-threatening condition characterized by a cluster of symptoms including agitation, hallucinations, rapid heart rate, fever, muscle stiffness or twitching, loss of coordination, nausea, vomiting, and diarrhea. It is more likely to occur when fluoxetine is taken with other medications that increase serotonin levels.
  • Suicidal Thoughts and Behaviors: Antidepressants, including fluoxetine, carry a risk of worsening depression and increasing suicidal thoughts or behaviors, particularly in children, adolescents, and young adults (under 25 years old), especially during the initial stages of treatment or when the dose is changed. A black box warning highlights this risk.
  • Hyponatremia: Low sodium levels in the blood, particularly in elderly patients or those taking diuretics. Symptoms can include headache, confusion, weakness, and unsteadiness.
  • Abnormal Bleeding: Increased risk of bruising or bleeding, especially when used with anticoagulants or antiplatelet drugs.
  • Mania or Hypomania: Fluoxetine can trigger manic or hypomanic episodes in individuals with bipolar disorder.
  • Angle-Closure Glaucoma: In susceptible individuals, fluoxetine may precipitate an angle-closure attack.

Contraindications and Precautions

Fluoxetine should not be used in patients who are taking, or have recently taken, monoamine oxidase inhibitors (MAOIs) due to the risk of serotonin syndrome. A washout period of at least 14 days is recommended after discontinuing an MAOI before starting fluoxetine, and vice versa.

Caution is advised in patients with a history of seizures, liver or kidney impairment, heart disease, or bleeding disorders. Pregnant and breastfeeding women should discuss the risks and benefits with their healthcare provider.

Drug Interactions

Fluoxetine can interact with a variety of other medications, potentially altering their effectiveness or increasing the risk of adverse effects. It is essential to inform your doctor about all medications, supplements, and herbal products you are taking.

Monoamine Oxidase Inhibitors (MAOIs)

As mentioned, concomitant use of fluoxetine with MAOIs (e.g., phenelzine, tranylcypromine, isocarboxazid, selegiline, linezolid) is contraindicated due to the risk of serotonin syndrome.

Other Serotonergic Drugs

Combining fluoxetine with other drugs that increase serotonin levels can also increase the risk of serotonin syndrome. This includes other SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans (used for migraines), fentanyl, lithium, tramadol, St. John's Wort, and certain illicit drugs like MDMA (ecstasy).

Drugs Affecting Bleeding

Fluoxetine can increase the risk of bleeding when taken with:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, naproxen, and aspirin
  • Anticoagulants like warfarin
  • Antiplatelet drugs like clopidogrel

CYP450 Enzyme Interactions

Fluoxetine is a potent inhibitor of the cytochrome P450 enzyme CYP2D6 and a moderate inhibitor of CYP2C19. This means it can significantly increase the blood levels of other drugs metabolized by these enzymes, potentially leading to toxicity. Examples include certain antipsychotics (e.g., risperidone, haloperidol), antiarrhythmics (e.g., flecainide, propafenone), beta-blockers (e.g., metoprolol), and other antidepressants (e.g., TCAs).

Other Interactions

Fluoxetine may also interact with:

  • Benzodiazepines: May increase the levels of some benzodiazepines.
  • Anticonvulsants: May affect the levels or efficacy of certain seizure medications.
  • Anticoagulants: As mentioned, increased bleeding risk.
  • Tricyclic Antidepressants (TCAs): Fluoxetine can significantly increase TCA plasma concentrations.

Patients should always provide a complete medication list to their healthcare provider to avoid potentially dangerous interactions.

Molecular Properties

Understanding the molecular characteristics of fluoxetine provides insight into its behavior and interactions within the body.

SMILES Notation

The Simplified Molecular Input Line Entry System (SMILES) notation for fluoxetine is: CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1

Molecular Formula

The molecular formula for fluoxetine is C17H18F3NO.

Molecular Weight

The molecular weight of fluoxetine is approximately 309.33 g/mol.

Structure Description

Fluoxetine is a chiral molecule, meaning it exists as two non-superimposable mirror images (enantiomers). The commercial product is typically a racemic mixture, containing equal amounts of both enantiomers, although the (S)-enantiomer is generally considered more potent. Chemically, it is N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine. The structure features:

  • A central propyl chain connecting an amine group and an ether linkage.
  • An N-methyl group attached to the amine nitrogen.
  • A phenyl ring directly attached to the propyl chain.
  • A phenoxy group attached to the propyl chain via an ether oxygen.
  • The phenoxy group is substituted with a trifluoromethyl (-CF3) group at the para position.

The trifluoromethyl group is highly electronegative and lipophilic, contributing to the drug's pharmacokinetic properties, such as its absorption and distribution. The chiral center is located at the carbon atom bearing the phenyl ring and the phenoxy group.

Analyze Fluoxetine with MolForge

Fluoxetine represents a significant advancement in psychopharmacology, offering a targeted approach to managing complex neurological and psychiatric conditions. Its efficacy, coupled with a generally manageable side effect profile, has cemented its role in modern medicine. However, like all pharmaceuticals, its therapeutic potential is intricately linked to its molecular structure, pharmacokinetic properties, and potential interactions.

For researchers and pharmaceutical professionals looking to deepen their understanding of fluoxetine or discover novel therapeutic agents, advanced computational tools are invaluable. MolForge's AI-powered platform offers state-of-the-art capabilities for molecular analysis, prediction, and drug discovery. You can explore fluoxetine's detailed molecular properties, predict its behavior in biological systems, identify potential drug targets, and even design new molecules with enhanced efficacy or safety profiles.

Ready to unlock the full potential of molecular exploration? Visit the MolForge dashboard today to leverage our AI tools and accelerate your research in pharmaceutical discovery.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

  • Bipolar affective disorder, current episode depression
  • Bulimia nervosa
  • Depressive disorder
  • Major depressive disorder
  • Obsessive-compulsive disorder
  • Panic disorder
  • Premenstrual dysphoric disorder

Off-label uses (6)

  • Cataplexy and narcolepsy
  • Fibromyalgia
  • Menopausal flushing
  • Postpartum depression
  • Posttraumatic stress disorder
  • Seasonal affective disorder

Contraindications (53)

  • Abnormal sexual function
  • Agranulocytosis
  • Angle-closure glaucoma
  • Anorexia nervosa
  • At risk for aspiration
  • Benign prostatic hyperplasia
  • Bipolar disorder
  • Blood coagulation disorder
  • Bradycardia
  • Carcinoma of female breast
  • Cerebrovascular accident
  • Cerebrovascular disease
  • Cirrhosis of liver
  • Conduction disorder of the heart
  • Dehydration
  • Diabetes mellitus
  • Disease of liver
  • Epilepsy
  • Esophageal dysmotility
  • Heart failure
  • Hepatic failure
  • Hypercholesterolemia
  • Hyperglycemia
  • Hyperlipidemia
  • Hyperprolactinemia
  • Hypertriglyceridemia
  • Hypomania
  • Hyponatremia
  • Hypovolemia
  • Leukopenia
  • + 23 more

Mechanism & targets

Mechanism of action (MoA)Serotonin Uptake Inhibitors
Established pharmacologic classSerotonin Reuptake Inhibitor

Molecular targets (41)

TargetGeneActionActivity
Sodium-dependent serotonin transporterSLC6A4inhibitorKd 9.09
Sodium-dependent serotonin transporterSlc6a4unknownKi 8.70
Alpha-2A adrenergic receptorADRA2AunknownKi 8.20
Sodium-dependent dopamine transporterSlc6a3unknownKi 7.97
Serotonin 1 (5-HT1) receptorHtr1a|Htr1b|Htr1d|Htr1funknownIC50 7.82
Sodium-dependent noradrenaline transporterSlc6a2unknownKi 7.07
5-hydroxytryptamine receptor 2CHtr2cunknownKi 6.96
AcetylcholinesteraseACHEunknownIC50 6.89
TransporterSlc6a2unknownKi 6.84
TransporterNETunknownKi 6.80
Sigma non-opioid intracellular receptor 1Sigmar1unknownKi 6.62
Sodium-dependent noradrenaline transporterSLC6A2unknownKd 6.62
5-hydroxytryptamine receptor 2AHTR2AunknownKi 6.61
5-hydroxytryptamine receptor 2AHtr2aantagonistKi 6.50
5-hydroxytryptamine receptor 2CHTR2CunknownKi 6.40
Adrenergic receptor alpha-1Adra1b|Adra1d|Adra1aunknownKi 6.22
Alpha-2B adrenergic receptorADRA2BunknownKi 6.16
Potassium voltage-gated channel subfamily H member 2KCNH2unknownIC50 6.16
Cytochrome P450 2D6CYP2D6unknownIC50 6.16
Sodium-dependent dopamine transporterSlc6a3unknownKi 6.11

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1987-12-29FDA—ELI LILLY AND CO

ATC classification

ATC codeTherapeutic hierarchy
N06AB03NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Selective serotonin reuptake inhibitors
N06CA03NERVOUS SYSTEM › PSYCHOANALEPTICS › PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION › Antidepressants in combination with psycholeptics

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • FDA label: CYP2D6 · Actionable PGx
  • HCSC label: CYP2D6 · Informative PGx
  • Swissmedic label: CYP2D6 · Informative PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Completed suicide3341.4
Serotonin syndrome3070.5
Intentional overdose2837.1
Toxicity to various agents2380.8
Suicide attempt1990.8
Suicidal ideation1956.7
Drug interaction1747.2
Drug abuse1016.3
Intentional self-injury999.1
Electrocardiogram QT prolonged841.8
Systemic lupus erythematosus670.2
Agitation669.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Fluoxetine is on its molecule page.

Molecular formulaC17H18F3NO
Molecular weight309.33 g/mol
CAS number54910-89-3
InChIKeyRTHCYVBBDHJXIQ-UHFFFAOYSA-N
PubChem CID3386
CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Fluoxetine used for?

DrugCentral lists the following indications for Fluoxetine: Bipolar affective disorder, current episode depression, Bulimia nervosa, Depressive disorder, Major depressive disorder, Obsessive-compulsive disorder, Panic disorder and Premenstrual dysphoric disorder.

How does Fluoxetine work?

Fluoxetine is classified as Serotonin Uptake Inhibitors; its molecular targets in DrugCentral include SLC6A4 (inhibitor), Slc6a4, ADRA2A and Slc6a3.

When was Fluoxetine first approved?

Fluoxetine was first approved by the FDA in 1987.

What drug class does Fluoxetine belong to?

Fluoxetine is in the Serotonin Reuptake Inhibitor class.

What is the chemical formula of Fluoxetine?

Fluoxetine has the molecular formula C17H18F3NO and a molecular weight of 309.33 g/mol.

Analyze Fluoxetine with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Ask About Fluoxetine

Have a question? Our AI can help (answers are AI-generated, not medical advice).

Browse: CNS & Neurological drug guides · all drugs starting with F · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases and includes AI-generated text. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.